Advances in biotechnology have become a defining feature of modern healthcare. Products such as gene therapy, stem cell therapy, and molecularly engineered vaccines are now central to global efforts to treat diseases that were previously difficult or impossible to manage. In Indonesia, the rapid pace of innovation, accelerated by lessons learned during the COVID-19 pandemic, has underscored the need for a regulatory framework capable of keeping pace with scientific development while safeguarding public health.
In response, the Indonesian Food and Drug Authority (Badan Pengawas Obat dan Makanan – BPOM) has introduced a new generation of biotechnology regulations. These rules are designed not only to ensure product safety, efficacy, and quality, but also to foster a regulatory environment that supports innovation and investment. Through more comprehensive oversight, Indonesia aims to align itself with global standards for advanced therapies while maintaining robust public protection against potential risks arising from complex biotechnological products.
BPOM’s Regulatory Framework for Biotechnology Products
BPOM’s latest regulations reflect Indonesia’s strategic response to global developments in biotechnology. Rather than merely updating existing rules, these instruments signal a policy shift toward integrating international regulatory standards into the national supervisory system.
A cornerstone of this framework is Food and Drug Authority Regulation No. 24/2025 on Procedures for Approval of New Drug Development (“BPOM Regulation 24/2025”). This regulation significantly tightens evaluation requirements by mandating more extensive pre-clinical and clinical data. The approach reflects a risk-based regulatory philosophy, recognizing that biotechnology products involve far greater scientific and biological complexity than conventional pharmaceuticals.
Article 2 paragraphs 1 and 2 of BPOM Regulation 24/2025 stipulate that any New Drug Development (Obat Pengembangan Baru or OPB) must obtain approval from the Head of BPOM before being used in clinical trials in Indonesia. The regulation defines OPB to include new drugs and biological products, advanced therapy products, biosimilar products, and other innovative products developed in line with scientific and technological progress in pharmaceuticals.
A fundamental shift introduced by this regulation is its emphasis on transparency and accountability. Approval is no longer a predominantly administrative exercise; it must be supported by scientifically defensible justification. Consequently, biotechnology companies are required to submit comprehensive pre-clinical and clinical data that meet internationally accepted methodological standards. While this increases the research and documentation burden, it also enhances legal certainty and strengthens product credibility in the eyes of regulators, investors, and patients.
Article 3 paragraphs 1 and 2 of BPOM Regulation 24/2025 further clarify that applications for OPB approval must be submitted electronically by eligible business actors, including pharmaceutical manufacturers, hospitals, drug manufacturing institutions, radiopharmaceutical production facilities, cell and stem cell processing laboratories, contract research organizations, and research institutions. This provision illustrates BPOM’s intent to regulate biotechnology development across its entire innovation ecosystem.
Complementing this framework is Food and Drug Authority Regulation Number 8 of 2025 on Guidelines for the Assessment of Advanced Therapy Products (“BPOM Regulation 8/2025”). This regulation replaces Food and Drug Authority Regulation Number 18 of 2020, which previously focused solely on human cell-based products. The new regulation adopts a broader scope, covering gene therapy, cell therapy, and other biomolecular products.
A key feature of BPOM Regulation 8/2025 is its focus on long-term risk assessment. Advanced therapy products often produce complex biological effects that may only become apparent after extended use. By incorporating principles derived from international standards developed by the World Health Organization (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), BPOM seeks to ensure that Indonesian biotechnology products are both safe for domestic use and competitive in global markets.
Both regulations are firmly grounded in Article 334 paragraph 3 of Law No. 17/2023 on Health (“Health Law”), which mandates the government to promote the utilization of domestically developed health technology products. This statutory foundation confirms that BPOM’s biotechnology regulations are not merely technical instruments, but part of a broader constitutional mandate to strengthen Indonesia’s national health ecosystem.
Also read: Precision Medicine: The Future of Personalised and Effective Healthcare in Indonesia
Impact on Biotechnology Development and Industry Dynamics
BPOM Regulation 24/2025 and BPOM Regulation 8/2025 have far-reaching implications for the direction of biotechnology development in Indonesia. By requiring more rigorous pre-clinical and clinical evidence, the regulations ensure that biotechnology products are built on robust scientific foundations that can withstand regulatory scrutiny.
For business actors, this translates into higher research and compliance costs. However, it also confers greater legitimacy on approved products. Compliance with standards aligned to WHO and ICH principles enhances the prospects of international recognition, facilitating access to foreign markets and cross-border partnerships.
From an innovation perspective, the regulatory impact is twofold. On one hand, longer and more complex approval processes may pose barriers for smaller biotechnology firms and start-ups with limited capital. Administrative requirements, laboratory certification, and regular regulatory audits demand significant financial and organizational resources. On the other hand, the clarity and predictability of the regulatory framework create a more attractive investment environment. Legal certainty encourages investors to commit capital, while universities and research institutions are incentivized to collaborate with industry in generating data that meets BPOM’s evaluation standards.
The regulations also promote a more integrated research ecosystem. The need for detailed and reliable data discourages isolated development efforts and encourages collaboration among industry players, academic institutions, research centers, and international partners. This collaborative model supports technology transfer, strengthens domestic laboratory capacity, and enhances human resource development in advanced biotechnology fields. As a result, although compliance obligations increase, the regulations function as a catalyst for aligning Indonesia’s biotechnology industry with global best practices.
Also read: Protecting Innovation: The Role of Patents in Biotechnology Drug Development
Strategic Responses to the New BPOM Regulatory Environment
To navigate BPOM’s updated biotechnology regulations effectively, companies in the healthcare and biotechnology sectors must adopt deliberate and forward-looking strategies. BPOM leadership has emphasized that oversight of biological products must encompass the entire product life cycle, from research and development to distribution. While stricter regulation increases compliance obligations, it can also drive sustainable industry growth if approached strategically.
First, companies should invest in compliance infrastructure and quality management systems. The requirement for comprehensive pre-clinical and clinical data necessitates laboratories that meet international standards, as well as the adoption of ISO-based systems, Good Laboratory Practice (GLP), and Good Manufacturing Practice (GMP). These measures not only satisfy BPOM requirements but also enable access to international markets with comparable standards.
Second, collaboration strategies are essential. Given the high cost and complexity of biotechnology research and clinical trials, partnerships with universities, research institutions, and international collaborators can enhance research capacity, accelerate technology transfer, and improve the quality of scientific outputs.
Third, companies should establish dedicated regulatory intelligence teams. These teams monitor regulatory developments, assess policy implications, and enable rapid strategic adjustments. Proactive regulatory awareness helps companies anticipate administrative challenges while capitalizing on policy initiatives that support domestic biotechnology development.
Fourth, sustainable financing strategies are critical. The new regulatory framework requires significant investment in research and compliance, prompting companies to explore diverse funding sources such as venture capital, research grants, and government-backed financing schemes. Adequate financial support ensures that clinical trials and regulatory processes can be conducted without undermining business continuity.
Finally, transparent public communication is increasingly important. BPOM regulations emphasize scientific accountability, making it essential for companies to communicate research outcomes and clinical trial results clearly to stakeholders and the public. Transparency enhances public trust and reinforces corporate credibility within the biotechnology sector.
BPOM’s latest biotechnology regulations represent both a regulatory challenge and a strategic opportunity. For companies unprepared to invest in research, compliance, and collaboration, the new framework may prove demanding. For those willing to adapt, however, it offers a pathway to stronger competitiveness, expanded market access, and integration into global biotechnology value chains. Ultimately, these regulations position Indonesia to emerge as a leading biotechnology development hub in Asia, supported by a robust legal framework that balances innovation with public protection.***
Also read: Indonesia’s Marine Biotechnology: Fueling a Sustainable Blue Economy
Daftar Hukum:
- Peraturan BPOM Nomor 24 Tahun 2025 tentang Tata Laksana Persetujuan Obat Pengembangan Baru (“PerBPOM 24/2025”).
- Peraturan BPOM Nomor 8 Tahun 2025 tentang Pedoman Penilaian Produk Terapi Advanced (“PerBPOM 8/2025”).
- Undang-Undang Nomor 17 Tahun 2023 tentang Kesehatan (“UU Kesehatan”).
Referensi:
- Peraturan BPOM Nomor 8 Tahun 2025, Regulasi untuk Dorong Pengembangan Produk Terapi Advanced di Indonesia. Badan POM. (Diakses pada 1 Desember 2025 pukul 08.06 WIB).
- Tren Terbaru dalam Regulasi Biofarmasi oleh Badan Nasional Pengawasan. Badan Nasional Pengawasan Biofarmasi dan Produk. (Diakses pada 1 Desember 2025 pukul 08.19 WIB).
- Kepala POM Soroti Tantangan dan Peluang Produk Biologi di Pasar Global. Badan POM. (Diakses pada 1 Desember 2025 pukul 09.20 WIB).